Gilead Sciences (GILD) Taps Session High as Biotech Rally Continues
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) hit session highs Thursday morning, rising nearly 5% as biotech continued to rally on easing pricing fears and sector rotation.
iShares Nasdaq Biotechnology (NASDAQ: IBB) traded higher by 1.65%, adding to recent gains.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Electra Therapeutics files for proposed IPO
- FDA approves Gilead's Bixlenvo HIV tablet for adults on complex regimens
- YouTube Probed By FTC Over Blocked Social Media Accounts - Bloomberg
Create E-mail Alert Related Categories
ETFs, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
